BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 21487529)

  • 1. Transformation of the 5q- syndrome to acute lymphoblastic leukemia: a report of two cases and review of the literature.
    Agostino NM; Ahmed B; Popescu D; Gheith S
    Int J Clin Exp Pathol; 2011 Mar; 4(3):322-6. PubMed ID: 21487529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired EVI1 rearrangement involved in the transformation from 5q- syndrome to pre-B lymphocytic leukemia in a Chinese patient.
    Liu D; Chen S; Pan J; Zhu M; Wu N; Zhu F; Chen Z
    Int J Hematol; 2012 Dec; 96(6):806-9. PubMed ID: 23054648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 5q- syndrome: biology and treatment.
    Padron E; Komrokji R; List AF
    Curr Treat Options Oncol; 2011 Dec; 12(4):354-68. PubMed ID: 21964863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.
    Jonasova A; Bokorova R; Polak J; Vostry M; Kostecka A; Hajkova H; Neuwirtova R; Siskova M; Sponerova D; Cermak J; Mikulenkova D; Cervinek L; Brezinova J; Michalova K; Fuchs O
    Eur J Haematol; 2015 Jul; 95(1):27-34. PubMed ID: 25284710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new recurrent translocation, t(5;11)(q35;p15.5), associated with del(5q) in childhood acute myeloid leukemia. The UK Cancer Cytogenetics Group (UKCCG).
    Jaju RJ; Haas OA; Neat M; Harbott J; Saha V; Boultwood J; Brown JM; Pirc-Danoewinata H; Krings BW; Müller U; Morris SW; Wainscoat JS; Kearney L
    Blood; 1999 Jul; 94(2):773-80. PubMed ID: 10397745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q.
    Mallo M; Cervera J; Schanz J; Such E; García-Manero G; Luño E; Steidl C; Espinet B; Vallespí T; Germing U; Blum S; Ohyashiki K; Grau J; Pfeilstöcker M; Hernández JM; Noesslinger T; Giagounidis A; Aul C; Calasanz MJ; Martín ML; Valent P; Collado R; Haferlach C; Fonatsch C; Lübbert M; Stauder R; Hildebrandt B; Krieger O; Pedro C; Arenillas L; Sanz MÁ; Valencia A; Florensa L; Sanz GF; Haase D; Solé F
    Leukemia; 2011 Jan; 25(1):110-20. PubMed ID: 20882045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10).
    Ureshino H; Kizuka H; Kusaba K; Sano H; Nishioka A; Shindo T; Kubota Y; Ando T; Kojima K; Kimura S
    Int J Hematol; 2017 May; 105(5):692-696. PubMed ID: 27914067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
    Möllgård L; Saft L; Treppendahl MB; Dybedal I; Nørgaard JM; Astermark J; Ejerblad E; Garelius H; Dufva IH; Jansson M; Jädersten M; Kjeldsen L; Linder O; Nilsson L; Vestergaard H; Porwit A; Grønbæk K; Hellström-Lindberg E
    Haematologica; 2011 Jul; 96(7):963-71. PubMed ID: 21719884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 5q-anomaly.
    Van den Berghe H; Vermaelen K; Mecucci C; Barbieri D; Tricot G
    Cancer Genet Cytogenet; 1985 Jul; 17(3):189-255. PubMed ID: 3891074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
    Aschauer G; Greil R; Linkesch W; Nösslinger T; Stauder R; Burgstaller S; Fiegl M; Fridrik M; Girschikofsky M; Keil F; Petzer A
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e143-9. PubMed ID: 26422252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined immunophenotyping and FISH identifies the involvement of B-cells in 5q- syndrome.
    Jaju RJ; Jones M; Boultwood J; Kelly S; Mason DY; Wainscoat JS; Kearney L
    Genes Chromosomes Cancer; 2000 Nov; 29(3):276-80. PubMed ID: 10992302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular dissection of the 5q deletion in myelodysplastic syndrome.
    Ebert BL
    Semin Oncol; 2011 Oct; 38(5):621-6. PubMed ID: 21943668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Routes of Clonal Evolution into Complex Karyotypes in Myelodysplastic Syndrome Patients with 5q Deletion.
    Feurstein S; Thomay K; Hofmann W; Buesche G; Kreipe H; Thol F; Heuser M; Ganser A; Schlegelberger B; Göhring G
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rare case of transformation of childhood myelodysplastic syndrome to acute lymphoblastic leukemia.
    Koh YR; Cho EH; Park SS; Park MY; Lee SM; Kim IS; Lee EY
    Ann Lab Med; 2013 Mar; 33(2):130-5. PubMed ID: 23483089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is 5q deletion in de novo Acute Myelogenous Leukemia (AML) with excess blasts a surrogate marker for the cryptic t(7;21)(p22;q22)? A case report and review of literature.
    Johnston RD; Sayedian FH; Mendiola C; Ehman W; Ortega V; Velagaleti GVN
    Cancer Genet; 2022 Apr; 262-263():30-34. PubMed ID: 34974291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?
    Gorshein E; Weber UM; Gore S
    Expert Rev Hematol; 2020 Mar; 13(3):233-239. PubMed ID: 32067540
    [No Abstract]   [Full Text] [Related]  

  • 17. Hybrid leukemia and the 5q-abnormality.
    Sun G; Wormsley S; Sparkes RS; Naeim F; Gale RP
    Leuk Res; 1991; 15(5):351-6. PubMed ID: 2046386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
    Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
    Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.
    Chen Y; Kantarjian H; Estrov Z; Faderl S; Ravandi F; Rey K; Cortes J; Borthakur G
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):341-4. PubMed ID: 22579233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q- syndrome from refractory anemia in primary myelodysplastic syndrome.
    Cermák J; Michalová K; Brezinová J; Zemanová Z
    Leuk Res; 2003 Mar; 27(3):221-9. PubMed ID: 12537974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.